$CMND News

Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial

Clearmind Medicine Completes Participant Recruitment For First Segment Of Part B Of Its Phase I/IIa Clinical Study Of CMND-100 To Treat Alcohol Use Disorder

Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder

Clearmind Medicine Publishes Patient Application In Japan For Its Compositions And Methods For Treating Dyskinesia

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

Clearmind Medicine Announces 1-For-8 Reverse Share Split, Effective October 5, 2026

NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration With Clearmind Covering LSD, Ketamine and Ibogaine Combinations

Clearmind Enhances U.S. IP Presence with Publication of Three Patent Applications Covering LSD, Ketamine and Ibogaine Combinations

Clearmind Medicine Announces Three U.S. Patent Applications Covering Novel Proprietary Combinations Of LSD, Ketamine And Ibogaine With N-Acylethanolamines Such As Palmitoylethanolamide

Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C.

Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results

Clearmind Medicine Says Yale University’s IRB Approves Initiation Of Patient Recruitment For Parts B And C Of Phase I/II Clinical Trial Evaluating CMND‑100

Clearmind Medicine Stock Slides Friday: What's Happening?

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine Initiates Phase lla, Double-Blind, Placebo-Controlled Phase I/IIa Clinical Trial Evaluating CMND-100 For Treatment Of AUD

SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Clearmind Medicine Advances Its IP Portfolio With Publication In U.S. Of Its Patent Application For Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines To Treat Post-Traumatic Stress Disorder

Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial